LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: Pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy

British Journal of Pharmacology

Volumn 125, Issue 6, 1998, Pages 1258-1266

  Potschka, H ^a   Loscher W ^a   Wlaz P ^a,d   Behl, B ^b   Hofmann, H P ^b   Treiber, H J ^c   Szabo, L ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Knoll AG   (Germany)

^c BASF SE   (Germany)

^d UNIVERSITY OF LIFE SCIENCES IN LUBLIN   (Poland)

Author keywords

AMPA; Anticonvulsant; Glutamate; Kainate; Neuroprotection; Seizures

Indexed keywords

4,5 DIHYDRO 1 METHYL 4 OXO 7 TRIFLUOROMETHYLIMIDAZO[1,2 A]QUINOXALINE 2 CARBONIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLUTAMATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONVULSION; DOSE RESPONSE; DRUG RECEPTOR BINDING; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; NONHUMAN; PRIORITY JOURNAL; RAT; TEMPORAL LOBE EPILEPSY;

EID: 0031795704     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702172     Document Type: Article

References (31)

1. BRISTOW, L.J., HUTSON, P.H., KULAGOWSKI, J.J., LEESON, P.D., MATHESON, S., MURRAY, F., RATHBONE, D., SAYWELL, K.L., THORN, L., WATT, A.P. & TRICKLEBANK, M.D. (1996). Anticonvulsant and behavioral profile of L-701, 324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J. Pharmacol.Exp.Ther., 279, 492-501.
2. CARTER, A.J. (1992). Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future, 17, 595-613.
3. CHIZH, B.A., CUMBERBATCH, M.J. & HEADLEY, P.M. (1994). A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord. Br. J. Pharmacol., 112, 843-846.
4. CLARKE, V.R.J., BALLYK, B.A., HOO, K.H., MANDELZYS, A., PELLIZZARI, A., BATH, C.P., THOMAS, J., SHARPE, E.F., DAVIES, C.H., ORNSTEIN, P.L., SCHOEPP, D.D., KAMBOJ, R.K., COLLINGRIDGE, G.L., LODGE, D. & BLEAKMAN, D. (1997). A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature, 389, 599-603.
5. COTMAN, C.W., KAHLE, J.S., MILLER, S.E., ULAS, J. & BRIDGES, R.J. (1995). Excitatory amino acid neurotransmission. In Psychopharmacology. The fourth generation of progress ed. Bloom F.E., & Kupfer D.J., pp. 75-85, New York: Raven Press.
6. DALGAARD, L., HJORTKJAER, R.K., REGNIER, B. & NORDHOLM, L. (1994). Pharmacokinetics of the neuroprotective glutamate antagonist Nbqx (6-nitro-7-sulfamoyl-benzo(F)quinoxaline-2- 3-Dione) in mice, rats, and dogs - interactions with probenecid. Drug Metab. Dispos., 22, 289-293.
7. DINGLEDINE, R., MCBAIN, C.J. & MCNAMARA, J.O. (1990). Excitatory amino acid receptors in epilepsy. Trends Pharmacol. Sci., 11, 334-338.
8. EBERT, U., RUNDFELDT, C. & LÖSCHER, W. (1995). Development and pharmacological suppression of secondary after discharges in the hippocampus of amygdala-kindled rats. Eur. J. Neurosci., 7, 732-741.
9. B receptor antagonist and a polyamine site antagonist in amygdala-kindled rats. Eur J. Pharmacol., 322, 179-184.
10. FOUTZ, A.S., PIERREFICHE, O. & DENAVITSAUBIE, M. (1994). Combined blockade of NMDA and non-NMDA receptors produces respiratory arrest in the adult cat. Neuroreport, 5, 481-484.
11. FREEMAN, F.G. & JARVIS, M.F. (1981). The effect of interstimulation interval on the assessment and stability of kindled seizure threshold. Brain Res. Bull., 7, 629-633.
12. 3H]kainate binding sites with different molecular target sizes in rat cortex. Neurosci. Lett., 65, 47-52.
13. 3H]AMPA, a structural analogue of glutamic acid, to rat brain membranes. J. Neurochem., 38, 173-178.
14. HÖNACK, D. & LÖSCHER, W. (1995). Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia, 36, 763-771.
15. LEES, G.J. (1996). Therapeutic potential of AMPA receptor ligands in neurological disorders. Cns. Drugs. 5, 51-74.
16. LIPPERT, K., WELSCH, M. & KRIEGLSTEIN, J. (1994). Over-additive protective effect of dizocilpine and Nbqx against neuronal damage. Eur J. Pharmacol., 253, 207-213.
17. LITCHFIELD, J.T. & WILCOXON, F. (1949). A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96, 99-113.
18. LÖSCHER, W. (1998a). Animal models of epilepsy and epileptic seizures. In Antiepileptic drugs. Handbook of experimental pharmacology ed. Eadie, M.J. & Vajda, F. Berlin: Springer, in press.
19. LÖSCHER, W. (1998b). New visions in the pharmacology of anticonvulsion. Eur J. Pharmacol., 342, 1-13.
20. LÖSCHER, W. (1998c). Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol., 54, 721-741.
21. LÖSCHER, W. & HÖNACK, D. (1991). Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol. Sci., 12, 52.
22. LÖSCHER, W. & HÖNACK, D. (1992). The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J. Pharmacol., 215, 199-208.
23. LÖSCHER, W. & HÖNACK, D. (1994). Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur J. Pharmacol., 259, R3-R5.
24. LÖSCHER, W., LEHMANN, H., BEHL, B., SEEMAN, D., TESCHENDORF, H.J., HOFMANN, H.P., LUBISCH, W., HÖGER, T., LEMAIRE, H.-G. & GROSS, G. (1998). A new pyrrolylquinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy. Eur. J. Neurosci. in press.
25. LÖSCHER, W., RUNDFELDT, C. & HÖNACK, D. (1993). Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci., 5, 1545-1550.
26. LÖSCHER, W. & SCHMIDT, D. (1994). Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res., 17, 95-134.
27. MARVIZÓN, J.C. & SKOLNICK, P. (1988). [3H]Glycine binding is modulated by Mg2+ and other ligands of the NMDA receptorcation channel complex. Eur J. Pharmacol., 151, 157-158.
28. MCMANIGLE, J.E., TAVEIRA DASILVA, A.M., DRETCHEN, K.L. & GILLIS, R.A. (1994). Potentiation of MK-801-induced breathing impairment by 2,3-dihydro-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. Eur J. Pharmacol., 252, 11-17.
29. MELDRUM, B.S. (1992). Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res., 12, 189-196.
30. NELLGARD, B. & WIELOCH, T. (1992). Cerebral protection by AMPA-receptor and NMDA-receptor antagonists administered after severe insulin-induced hypoglycemia. Exp. Brain Res., 92, 259-266.
31. RACINE, R.J. (1972). Modification of seizure activity by electrica. stimulation: II. Motor seizure. Electroenceph. Clin. Neurophysiol., 32, 281-294.